CMLD012612 manufacturers
- CMLD012612
-
- $1980.00
-
2026-05-11
- CAS:2368900-35-8
- Purity:
- Supply Ability: 10g
- CMLD012612
-
- $1980.00
-
2025-08-22
- CAS:2368900-35-8
- Purity:
- Supply Ability: 10g
|
| | CMLD012612 Basic information |
| | CMLD012612 Chemical Properties |
| Boiling point | 721.6±70.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 12.37±0.70(Predicted) | | form | Solid | | color | White to light yellow |
| | CMLD012612 Usage And Synthesis |
| Uses | CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity[1]. | | in vivo | CMLD012612 (0.5 mg/kg; intraperitoneal injection; for 3 hours; female C57BL/6 mice) treatment effectively suppresses liver polysomes 3 hours after injection, indicating inhibitory activity toward protein synthesis[1].
When administered to mice bearing myr-Akt/Em-Myc lymphomas, CMLD012612 (0.2 mg/kg; intraperitoneal injection; daily; for 5 days; female C57BL/6 mice) treatment effectively synergizes with Doxorubicin, leading to complete tumor loss[1]. | Animal Model: | Female C57BL/6 mice[1] | | Dosage: | 0.5 mg/kg | | Administration: | Intraperitoneal injection; for 3 hours | | Result: | Effectively suppressed liver polysomes 3 hours after injection.
|
| | IC 50 | eIF4 | | References | [1] Chu J, et al. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors. Cell Chem Biol. 2019 Nov 21;26(11):1586-1593. DOI:10.1016/j.chembiol.2019.08.008 |
| | CMLD012612 Preparation Products And Raw materials |
|